About VaccineNation
The Vaccine Nation blog will cover all the latest developments in the vaccine space from basic immunology to manufacture and access, across all diseases. Visit us regularly to get updates on COVID, find the most innovative platforms and see how the industry is constantly adapting its public and private health investments.
Our key themes will be split under:
Therapeutic
Technology
Infection
Global Health
We are the team behind the biggest and most established vaccine meetings: World Vaccine Congress Series that take place 3 times a year in Washington D.C., San Diego and Europe.
World Vaccine Congress Europe
World Vaccine & Immunotherapy Congress
World Vaccine Congress Washington
MOST POPULAR THIS MONTH
HDT Bio and UTMB partner against CCHFV and NiV
In November 2022 HDT Bio Corp. and the University of Texas Medical Branch (UTMB) revealed that they had been awarded a project agreement worth up to $87.4 million. The US Department of Defence’s (DOD) Joint Programme Executive Office for Chemical, Biological,...
Marking World AIDS Day 2022: “equalise” theme
1st December 2022 is World AIDS Day, with global communities observing it under the theme “equalise”. This year, the WHO is calling on “leaders and citizens” to identify and address the inequalities that challenge progress in “attaining the global goal to end AIDS by...
US announces further Global Health Security Partnerships
In November 2022 the White House issued a statement indicating the intention of the Biden-Harris Administration to continue to “prioritise global health security” as part of wider efforts in “national biodefence”. Highlighting ongoing outbreaks alongside the continued...
PharmaJet announces grant from NIH for HPV
In November 2022 PharmaJet announced that it had received an NIH grant of $800,000 towards their Phase II investigation of the immunogenicity of intradermal administration of a human papillomavirus (HPV) vaccine. Using PharmaJet’s Tropis intradermal (ID) needle-free...
WHO approval for Republic of Korea regulator
The WHO announced in November that the Ministry of Food and Drug Safety (MFDS), Republic of Korea, achieved maturity level 4 (ML4) in its ranking of regulatory authorities for medical products. This is the highest level. Out of 33 countries assessed, only the Republic...
CEPI collaboration with UQ on Disease X platform
In November 2022 CEPI announced an investment of U$5.7 million towards the development of a second-generation molecular clamp vaccine platform at the University of Queensland (UQ). This platform will be aimed at “combatting the next Disease X”. The funds will...
WHO: Monkeypox virus gets rebranded as Mpox
The WHO announced in November 2022 that, after “consultations with global experts”, it will begin using a preferred term “mpox” for monkeypox. While the word monkeypox is “phased out” both terms will be used simultaneously for one year. This move is made in attempts...
Exclusive interview with Dr Ariel Weinberger
With the World Vaccine and Immunotherapy Congress kicking off in San Diego today we are delighted to share another exclusive interview with the community. We were lucky to hear from Dr Ariel Weinberger, founder and CEO of Autonomous Therapeutics since 2017. Autonomous...
